Mosliciguat with TreprostinilA Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Sponsor:

Pulmovant, Inc.

Code:

NCT07333183

Conditions

Pulmonary Hypertension

Interstitial Lung Disease (ILD)

Lung Diseases

Vascular Diseases

Cardiovascular Diseases

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

inhaled mosliciguat

Dry Powder Inhaler

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-24. This information was provided to ClinicalTrials.gov by Pulmovant, Inc. on 2026-04-22.